Absci 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Everyone, I think we're ready to get started here. Thanks again for joining us for the Guggenheim Healthcare Innovation Conference this year on day two, moving to the afternoon sessions. I'm Vamil Divan, one of the biopharma analysts here at Guggenheim. Joined on the Guggenheim side up on stage with me, Arseniy Shabashvili, one of the members of the team. From the company side, very pleased to have Absci join us. We have Alex Khan, Corporate Vice President for Finance and Investor Relations, joining us here. Thanks, Alex, for coming to the conference again. Obviously, a very busy time at Absci. Lots changed over the last 12 months since we saw you here last.
Maybe for those less familiar with the company or maybe following it as closely, just a little bit of background on the Absci story and some of the key developments, and then we'll go from there on the questions.
Absolutely. Thank you, Vamil and Guggenheim, for hosting us again. Always a pleasure to be here. For those who've been following us for a while, you've probably seen our evolution over time from an AI drug creation platform company that was working with a number of partners on the pharma side to where we are today, which is a pipeline-owning company that is building out a pipeline of our own antibody programs. Right now, our lead program, ABS-201, is in a phase I-IIa study for pattern hair loss and also for endometriosis, are the two indications we're looking at. That's an anti-prolactin receptor antibody, which I know we'll get into some details.
That's what we see as our flagship program, and then we have some potential additional indications we're looking at for prolactin biology that we think could be very interesting to look at, whether it be within the ABS-201 molecule as an indication expansion, like we went from pattern hair loss to endometriosis, or some additional prolactin antibodies behind that. There's also some other molecules we have earlier stage in our pipeline that are outside of prolactin that we think could be interesting as well. Continuing to build out that pipeline that we have.
Okay, great. Let's dive into 201, because I think that's obviously where most of the focus is right now. You mentioned prolactin receptor. What was it about that receptor that drove the company to choose that as a target for your lead program here?
Yeah, no, there's a very interesting history on it. Our now retired head of R&D, Andreas Busch, he had previously been at Bayer, and he was working with the team there that had been looking at the prolactin mechanism for endometriosis at that time. They had, he and the team, a serendipitous discovery that the prolactin mechanism was not only implicated in endometriosis, but also in androgenetic alopecia or pattern hair loss, and they determined that while doing these animal studies. At the time, they had looked at those results in mice and also in stump-tailed macaques, which is a species of non-human primate that naturally goes bald after adolescence, much like humans. Andreas had been looking at moving that forward, and the team there decided to deprioritize that indication and look at some other things.
When Andreas had come over to Absci, first as a board member and then as our head of R&D in-house, this was a program and an indication that he was very excited about. This was biology that he was saying was very overlooked, very underappreciated, and that it was something that Absci should be pursuing. We started on that program a couple years ago now. We're in the phase I/IIa right now. We put out that SAD data in June from the IV portion of that, and we have the MAD portion ongoing right now. But it's a very unique mechanism. It looks to be regenerative in nature, very different from other programs in development, and very different from any other hair regrowth agents that we see out there right now.
Okay. Maybe you can talk more specifically around that as you think about the biology and the connection here, both for hair loss and endometriosis.
Yeah. Just elaborate further on what gets you excited.
Yeah, I mean, when the team there and now at Absci have been looking into the biology of, well, what exactly is the connection between prolactin receptor, and the hair cycle, it does look like the buildup of prolactin in the follicle is actually responsible for pushing the follicle into the apoptosis or regression phase of the hair cycle, which is the catagen phase. By blocking that buildup of prolactin in the follicle, you should be able to push the follicle back into the active phase, which is that anagen phase, which, depending on your biology for a particular human, can last a few years, right? Two years, four years, six years. Similarly, with endometriosis, excuse me, we see in the literature is that the buildup of prolactin in the endometrium could be responsible for two things.
One is the actual creation and formation of the lesions there, but also the pain perception that people feel when those lesions are growing. The study that we'll be planning to do next year as our phase II for endometriosis will be measuring pain growth, so looking at non-menstrual pain, dysmenorrhea. We do believe that the mechanism has the potential to be disease-modifying in that it could help with the lesion growth as well.
Okay. Let's talk pattern hair loss first, and then we'll come back to the endometriosis side. You mentioned how this looks different than anything else that's available or in development for pattern hair loss. Maybe you can elaborate on this. Kind of from the sort of profile you're looking at to develop with 201.
Yeah, I mean, I think what we look at as being a potential winning product for ABS-201 or for just a hair loss agent in general is something that would be safe, efficacious, convenient, and durable. When we think about the ABS-201 target product profile, what we are looking to develop is something that would be convenient in either getting two or three doses over a six-month period that can then give you multi-year durability after that, once you are off treatment, with obviously a good safety and then some good efficacy there. We can contrast that to something that is a chronic daily administration, a daily pill, a daily topical, or certain administrations like platelet-rich plasma treatments, like nutraceuticals, like hair transplants.
The ABS-201 target product profile is designed to be something that a consumer can take a few infrequent injections and see multi-year durability after that, versus something like a minoxidil, for example, where a lot of consumers in practice will be using this on a daily basis. If you come off treatment, you do not see that durability that you would have if you were continuing to take it. Again, contrast that to something like a prolactin receptor antibody, where the preclinical data we saw with the stump-tailed macaque suggests that even if you are having this infrequent dosing and then come off the dosing, you will still see that durability as you saw in the stump-tailed macaques.
What they saw was in, I think, 28 weeks, getting dosed every two weeks, but after those 28 weeks were up, you look out six months, two years, and four years later, those macaques still had all the hair that they had grown while they were on treatment. We can contrast that with something like a minoxidil, where once you come off that treatment, once you are no longer taking it, you are more likely or you are likely to lose that hair that you would have been growing in that time period.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
